Background {#Sec1}
==========

A large prospective cohort study comparing the painfulness of 179 surgical procedures revealed that even 'minor' operative procedures may be associated with considerable pain (mean maximum pain scores within the first 24 h of 6--7 on the numeric rating scale (NRS) to 10) \[[@CR1]\]. The 40 procedures associated with the highest mean pain scores included 22 distinct orthopedic/ trauma surgery procedures \[[@CR1]\]. So why was insufficient analgesia so common? Most participating hospitals routinely used multimodal pain concepts based on oral opioids in combination with non-opioids, but the study patients had received rather low cumulative oral opioid doses compared to studies reporting on postoperative patient-controlled i.v. (i.v. PCA) morphine administration \[[@CR1]\]. Moreover, pain scores in musculoskeletal surgery patients may not decrease at all during the first 24 h after surgery \[[@CR2]\]. Thus, optimization of peri-operative analgesia regimens with respect to meeting procedure-specific opioid analgesic requirements on the one hand and minimizing opioid-related side effects on the other hand still constitutes an urgent medical need and a major clinical challenge.

Previous studies have shown that preemptive analgesia regimens based on oral extended-release opioids (oxycodone or buprenorphine, respectively) -starting with the first dose as premedication- provided improved pain control with a lower rate of side effects compared to conventional i.v. morphine PCA in spine and orthopedic surgery \[[@CR3]--[@CR6]\]. However, when trauma surgery patients were treated with oxycodone, the rate of constipation was high (46%) \[[@CR7]\]. One way of addressing this particular side effect is an oral post-operative pain regimen based on the fixed combination of oxycodone with the μ-opioid receptor antagonist naloxone. Oral naloxone has a low bioavailability (\< 3%) and, therefore, is supposed to exert its opiate antagonistic effects almost entirely in the gut to ameliorate opiate-induced bowel paralysis. However, the risk of nausea and vomiting was unaffected by naloxone \[[@CR8], [@CR9]\]. As an alternative, tapentadol, an opioid with a dual mode of action (μ-receptor agonist/ norepinephrine reuptake inhibitor) is now available for the treatment of medium to severe pain conditions. Efficacy/safety of tapentadol immediate-release (IR) in post-operative pain management have been documented \[[@CR10]--[@CR12]\]. In both acute and chronic pain, tapentadol was associated with less gastro-intestinal side effects compared to oxycodone \[[@CR13], [@CR14]\]. The aim of this study was to evaluate and compare an analgesic regimen based on extended-release (ER) oxycodone/naloxone (Targin®, Mundipharma GmbH, Germany) to a regimen based on extended-release tapentadol (Palexia®, Grünenthal GmbH, Germany) in trauma surgery patients with respect to (1) analgesic efficacy and (2) safety as revealed by the incidence of opioid-induced side effects (nausea, vomiting, constipation, sedation, vertigo and somnolence, respectively). The study was powered to detect superiority of tapentadol for at least one endpoint pending statistical proof of non-inferiority of tapentadol for both endpoints in a first step.

The study design was based on equianalgesic starting doses -- either 10 mg oxycodone or 50 mg tapentadol \[[@CR10], [@CR11], [@CR15]--[@CR17]\].

Methods {#Sec2}
=======

Study design and study population {#Sec3}
---------------------------------

This randomized controlled observer-blind prospective clinical trial was approved by the German Competent Authority (BfArM, Nr. 4,038,588) and the Ethics Committee of Hannover Medical School (Nr 5897 M), and was registered at <https://eudract.ema.europa.eu> (EudraCT number 2011--003238-15) by Gertrud Haeseler October 2012. Principal investigator was Dirk Schaefers. The study was conducted at two hospital sites (Marien-Hospital Marl and St. Elisabeth-Krankenhaus Dorsten, later referred to as study sites 1 and 2) operated by one trust (Katholisches Klinikum Ruhrgebiet Nord GmbH, Marl, Germany) in cooperation with scientists affiliated at Hannover Medical School. Adult (≥ 18 years) trauma surgery patients ASA I-III were enrolled after written informed consent. Exclusion criteria were: inability to give informed consent, pregnancy or breast-feeding, pre-existing chronic pain treated with opiates, severe renal or hepatic impairment, and treatment with MAO- inhibitors.

Study procedures and peri-operative management {#Sec4}
----------------------------------------------

Patients were randomized to receive either the test intervention tapentadol ER (Palexia retard®) or the control intervention oxycodone/naloxone ER (Targin®) by the Institute for Biostatistics, Hannover Medical School. Randomization was stratified for sex and study site.

The first dose of tapentadol (50 mg) or oxycodone/naloxone (10/5 mg) was given as premedication. The analgesic regimen then continued according to the initial allocation. Anesthesia was induced and maintained with propofol 4 mg/kg/h and remifentanil 0.15--0.25 μg/kg/min as total intravenous anesthesia (TIVA) adjusted to obtain stable cardiovascular parameters with no fluctuations in response to surgical stimuli. Adjunctive long-acting intravenous opioids and PONV prophylaxis were at the discretion of the anesthetist and subject to secondary analysis. Risk factors for post-operative nausea and vomiting (PONV) like female sex, no smoking habit, anticipated post-operative opioid analgesia and history of PONV were documented.

Post-operative pain in the recovery room was treated with intravenous piritramide and the second oral dose of study medication. The patient was observed for an hour following the second dose of study medication and discharged when he was comfortable without further opioid requirement. The cumulative dose of oral study medication (tapentadol or oxycodone/naloxone, respectively) established as effective (premedication dose plus eventual supplemental doses in the recovery room) was continued 2× daily on the surgical ward. Analgesia was supplemented with non-opioids dipyrone or acetaminophen, and/or a coxib, respectively, to achieve a residual pain score up to 3--4. In case that this level of analgesia was not obtainable, a trauma surgery consultant was involved to address surgical reasons. If there were none, opioid doses were increased. The doses of coxibes were not standardized in this study as we included ASA I-III patients and had no restrictions with respect to higher age, cardio-vascular disease and /or moderately comprised renal function- which may represent contra-indications for the use of coxibes. Thus, coxibes were prescribed after individual risk/benefit-analysis.

### Rescue-interventions {#Sec5}

Nausea and vomiting: metoclopramide, ondansetron, dimenhydrinate and/or droperidolConstipation: As gastro-intestinal tolerability with respect to constipation is reported to be higher in both tapentadol and oxycodone/naloxone compared to oxycodone without naloxone, routine prophylactic laxatives are not generally recommended and we used the following rescue medication when constipation was observed: oral PEG 3350 (macrogol); oral sodium picosulfate, oral or rectal bisacodyl, oral lactuloseCentral-nervous side effects (sedation, vertigo, somnolence): Reduction of study medication

When pain intensities decreased, the study medication was stepwise reduced. The treatment algorithm is depicted in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Algorithm of analgesic therapy and concomitant medication

Data collection {#Sec6}
---------------

The maximum pain levels quantified by patients on a numeric rating scale (NRS) from 0 (no pain) to 10 (maximum conceivable pain) during exercise and at rest as well as opioid side effects incidence and severity were obtained once a day by a blinded investigator and 3-times daily by non-blinded staff. Constipation was noted when the patient had no daily defecation. Sedation included only mild levels of drowsiness with the patient easy to awake as opposed to somnolence where the patient was difficult to awake. All therapeutic interventions including dosing of the study medication, of additional non-opioid analgesics and rescue medication were documented by non-blinded investigators. Dosing of long-acting intravenous opioids during anesthesia and in the recovery room and PONV risk factors and prophylaxis were obtained from the anesthesia protocols. The primary endpoints were derived from blinded observations only.

Primary endpoints {#Sec7}
-----------------

There were 2 co-primary endpoints:Analgesic efficacy defined as the mean NRS level during exercise over the 5 days observation period.Safety measured by the incidence and severity (score 1--2) of side-effects. Score 1 is side effect observed but no requirement for intervention, 2 is side effect requiring intervention. The sum scores for each side effect over the five days observation period were calculated (maximum: 10) as well as the overall sum score across all side effects (maximum: 60). We defined, that a patient had a relevant side effect event at a sum score over the 5-days observation period of constipation ≥1nausea ≥3vomiting ≥3somnolence ≥1sedation ≥3vertigo ≥3, and/oroverall sum score ≥ 5.

The primary endpoint was occurrence/non-occurrence of relevant side effect events. The differential weighted ranking of the severity of the side effects took into account that constipation and somnolence are potentially dangerous, resulting in either bowel paralysis or respiratory depression. Nausea, vomiting, sedation and vertigo were considered clinically relevant only if they persisted at least during two days of opiate therapy with intervention, or during three days without intervention. The decision to intervene in case of side effects was individualized according to the patient's need.

Primary objectives {#Sec8}
------------------

Superiority of the tapentadol-based regimen would only be concluded when tapentadol was superior in at least one of the co-primary endpoints (pain or side effects) and not inferior in any of the two co-primary endpoints. Thus, the study formally had four primary objectivestapentadol is non-inferior to oxycodone/naloxone regarding pain during exercise with a non-inferiority margin of 1, andtapentadol is non-inferior to oxycodone/naloxone regarding occurrence of relevant side effects with a non-inferiority margin of 5%, andeithertapentadol is superior to oxycodone/naloxone regarding pain during exerciseortapentadol is superior to oxycodone/naloxone regarding occurrence of relevant side effects (or both (3) and (4)).

Secondary endpoints and objectives {#Sec9}
----------------------------------

Mean NRS-level at restSeparate analysis of patients with high pain scores at the end of the observation period (NRS ≥ 5)Required daily doses of study medication, concomitant non-opioid medication and intra-operative long-acting intravenous opioidsType and dosing of rescue medicationAnalysis of expected and unexpected adverse eventsTotal duration of post-operative opioid requirementPatient satisfaction at the end of the 5 days observation period

Sample size calculation and statistical analysis {#Sec10}
------------------------------------------------

Sample size estimation was performed in nQuery Advisor 7.0. It was predefined that the tapentadol-based regimen was superior if three of the four hypotheses were proven. The one-sided type-I-error was α = 2.5% for the non-inferiority hypotheses (1) and (2) and α = 1.25% for the superiority hypotheses (3) and (4) with a Bonferroni-correction. In order to reach an overall power of 80%, the power for each objective was set to 93%. A two-group t-test, and a two-group t-test for equivalence, respectively, were used for sample size calculation for the objectives related to pain. For the objectives related to the occurrence of side effects, a chi-square test with continuity correction and an equivalence test for the comparison of two proportions were used. Data were available from a phase III clinical study showing a more than 5% higher incidence of gastro-intestinal side effects with oxycodone compared to tapentadol \[[@CR11]\], and from a pre-study observation showing higher pain scores (one point) in the oxycodone/naloxone group with a standard deviation of 1.4 and, at the same time, a 21% higher incidence of side effects (35% vs. 14%). The overall sample size of the study was resulting from the objective with the highest necessary sample size, i.e. *n* = 123 patients per group as calculated for hypothesis (4). A low drop-out rate (\<5--10%) was expected due to the inpatient setting and the short duration of observation. The final sample size to be recruited was increased to *n* = 133 patients per treatment arm.

Primary population and analysis {#Sec11}
-------------------------------

In the analysis of the non-inferiority hypotheses, the per-protocol (PP) population was used. Superiority hypotheses were evaluated in the intention-to-treat (ITT) population. For the analysis of pain during exercise, a linear regression model was applied with the mean pain level of the first 5 post-operative days as dependent variable, and treatment, center and sex as independent factors. The treatment difference in pain and the corresponding 95% confidence interval (CI) were derived from the regression analysis and compared to the predefined non-inferiority margin of 1. Evaluation of treatment differences in the occurrence (yes/no) of relevant side effects was done using a Mantel-Haenszel-estimator for the risk difference, stratified by center and sex. The corresponding 95% confidence interval was calculated and compared to the predefined non-inferiority margin of 5%.

Secondary analyses {#Sec12}
------------------

Demographic and baseline characteristics, dosing of concomitant analgesic and rescue medication were compared by a two-sample t-test for numeric variables. Dichotomous secondary outcome data like incidence of side effect events yes/no were compared using a chi-square test. Associations between treatment group and secondary continuous outcome variables (e.g. pain at rest, treatment duration, and patient satisfaction) were analysed by linear regression with study medication as independent factor adjusted for study site and sex. Effect sizes are presented as differences in means with corresponding 95% CIs. The primary analysis was adjusted for sex and study site. The influence of further risk factors, e.g. BMI as continuous variable or PONV prophylaxis, was analysed by extended regression models (including treatment, center and sex, and additional risk factors). Again, linear regression was used for continuous outcomes. Logistic regression was used for categorical outcomes, especially occurrence of side effects. Odds ratios with corresponding 95% CIs are presented.

Results {#Sec13}
=======

A total of 831 patients were assessed for eligibility. Of these, 266 patients were randomized to tapentadol (*n* = 133) and oxycodone/naloxone (*n* = 133) within a time frame of two years. Only two patients were lost to follow-up (1× fatal pulmonary embolism during surgery unrelated to the study, 1× transfer to another hospital before surgery), see Fig. [2](#Fig2){ref-type="fig"}.Fig. 2Study flow chart. A total of *N* = 266 patients were enrolled, 133 in each treatment arm. Two patients of the oxycodone/naloxone group and no patients in the tapentadol group were lost to follow-up. Reasons for loss to follow-up were not related to the allocated treatment (1× logistic reasons before pre-treatment and surgery, 1× death following surgery due to pulmonary embolism)

Baseline patient characteristics were similar in the two study groups, see Table [1](#Tab1){ref-type="table"}.Table 1Baseline characteristics of the per-protocol study populationPatient and surgery characteristicsTapentadol\
(*n* = 133)Oxycodone/Naloxone\
(*n* = 131)Total\
(*n* = 264)Study site 165 (49%)65 (50%)130 (49%) 268 (51%)66 (50%)134 (51%)Age (in years)60 ± 1959 ± 1959 ± 19Female sex86 (65%)83 (64%)169 (64%)Smoker27 (20%)26 (20%)53 (20%)BMI (in kg/m^2^)27 ± 626 ± 527 ± 5Number of risk factors for PONV 116 (12%)14 (11%)30 (11%) 238 (29%)43 (33%)81 (31%) 361 (46%)56 (43%)117 (44%) 418 (14%)18 (14%)36 (14%)Prophylaxis of PONV None49 (37%)56 (43%)105 (40%) Single56 (42%)50 (38%)106 (40%) Double27 (20%)25 (19%)52 (20%) Triple1 (0.8%)0 (0.0%)1 (0.4%)Type of surgery Open reduction and internal fixation (ORIF)103 (77%)98 (75%)201 (76%) Closed reposition and intramedullary nailing10 (8%)9 (7%)19 (7%) Joint replacement9 (7%)14 (11%)23 (9%) Reconstruction of ligaments and muscle10 (8%)10 (8%)20 (8%) Fixateur externe1 (0.8%)0 (0.0%)1 (0.4%)Duration of surgery (in minutes)78 ± 4178 ± 4378 ± 42

Primary efficacy results (pain reduction during exercise in the two study groups) {#Sec14}
---------------------------------------------------------------------------------

Mean adjusted daily pain levels during exercise in the first five post-operative days were 2.8 ± 1.3 (tapentadol, mean ± SD) and 2.8 ± 1.3 (oxycodone/naloxone; difference in means 0.03 \[95% CI, −0.28 to 0.34\]; *p* = 0.8). Mean maximum pain intensity during exercise in the first 24 h after surgery was 3.8 ± 1.9 (tapentadol) and 3.8 ± 2.1 (oxycodone/naloxone; difference in means −0.06 \[95% CI, −0.54 to 0.42\]; *p* = 0.8). Pain intensities during exercise decreased with time to a mean level of 2.0 ± 1.7 (tapentadol) versus 2.0 ± 1.5 (oxycodone/naloxone; difference in means −0.08 \[95% CI, −0.46 to 0.30\]; *p* = 0.7) on day 5. Maximum pain levels during exercise over five post-operative days beginning with the day of the operation (day 1) are depicted in Fig. [3b](#Fig3){ref-type="fig"}. In the primary analysis, non-inferiority of tapentadol regarding pain during exercise could be confirmed as the upper bound of the 95% confidence interval for the pain difference (tapentadol- oxycodone/naloxone) was below the pre-defined non-inferiority margin of 1. Superiority of tapentadol concerning pain during exercise could not be concluded.Fig. 3**a**, *top*) Pain scores at rest and **b**, *below*) pain scores during exercise during the first 5 days following the operation beginning with the day of the operation (day 1) on the NRS from 0 (no pain) to 10 (worst pain imaginable). *Box edges* indicate 25th and 75th percentiles. Whiskers indicate 5th and 95th percentiles. Pain intensities at rest were low already on day 1 in both groups, pain intensities during exercise decreased with time to a mean level of 2 in both groups on day 5

There was a weak association between the cumulative dose (mg ME) of intra-operative i.v. opioids other than the short-acting remifentanil (fentanyl, sufentanil and/or piritramide) and pain reduction during exercise on day 1 (difference in means −0.02 \[95% CI, −0.04 to 0.00\]; *p* = 0.04). In the tapentadol group patients had received lower doses of long-acting opioids intra-operatively (15 ± 9 vs. 18 ± 13 mg morphine equivalent (*p* \< 0.03)). There was no difference between the groups with respect to post-operative piritramide requirement and concomitant non-opioid analgesic medication (see [Appendix 1](#Sec26){ref-type="sec"} and [Appendix 2](#Sec27){ref-type="sec"}).

Primary safety results (differences between the study groups with respect to incidence of side effects) {#Sec15}
-------------------------------------------------------------------------------------------------------

Vomiting on day 1 occurred in 11% of the tapentadol and in 16% of the oxycodone/naloxone patients (*p* = 0.60). The incidence of constipation was 35% in the tapentadol vs. 30% in the oxycodone/naloxone group (*p* = 0.33). The incidence of a sedation/ vertigo event was \<10%, somnolence \<2% in both groups (*p* \> 0.3, respectively). The incidence of side effect events in the two groups is depicted in Table [2](#Tab2){ref-type="table"}. Despite similar scores of relevant side effects (tapentadol 51% vs. oxycodone/naloxone 49%; risk difference 3% \[95% CI, −8 to 14%\]; *p* = 0.6), non-inferiority of tapentadol could not be concluded because the upper bound of the 95% confidence interval for the risk difference (tapentadol -- oxycodone/naloxone) was 14% and thus exceeding the predefined non-inferiority margin of 5%.Table 2Incidence of relevant side effect eventsTapentadolOxycodone/naloxoneFrequency (Percent)Frequency (Percent)*p*-value (CHI^2^)Nausea (≥3)17 (13%)23 (18%)0.23Vomiting (≥3)4 (3%)10 (8%)0.09Constipation (≥1)47 (35%)39 (30%)0.33Sedation (≥3)8 (6%)12 (9%)0.33Vertigo (≥3)7 (5%)5 (4%)0.57Somnolence (≥1)3 (2%)1 (0.8%)0.32Overall AE score (≥5)40 (30%)43 (33%)0.63Relevant adverse event68 (51%)63 (48%)0.62The severity of the respective side effect was rated with a daily score of 0--2, where 0 is absence of the respective side effect, 1 is side effect observed but no requirement for intervention, 2 is side effect requiring intervention. We defined, that a patient had a relevant side effect event at a sum score over the 5-days observation period of constipation and/or somnolence ≥1 and/or nausea, vomiting, sedation and/or vertigo ≥3, and/or an overall sum score ≥ 5

The unadjusted risk for nausea and vomiting was lower in the tapentadol group (Odds Ratios of 0.6 and 0.4), while the risk of constipation was higher (Odds Ratio 1.3). However, a multivariate regression analysis including PONV prophylaxis and risk factors to the logistic regression model revealed that the differences in the incidence of PONV between the treatment groups could be explained by confounding effects of PONV risk factors and PONV prophylaxis, now only leading to a treatment Odds Ratio of 0.98. Type and dose of rescue medication against nausea, vomiting and constipation is depicted in [Appendix 3](#Sec28){ref-type="sec"} and [Appendix 4](#Sec29){ref-type="sec"}.

Incidence and severity of central-nervous side effects was low in both treatment arms. Somnolence was noted in three patients allocated to tapentadol and in one patient allocated to oxycodone/naloxone. In one patient (tapentadol) the finding of somnolence in the blinded observation was not consistent with the unblinded observation. In the three other cases, passing somnolence was noted in the immediate post-operative period in the intermediate-care unit in higher aged patients not requiring discontinuation of study medication.

Secondary results: Pain at rest, dosing of post-operative study medication {#Sec16}
--------------------------------------------------------------------------

Mean pain at rest in the first five post-operative days was 1.5 ± 1.1 (tapentadol, mean ± SD) versus 1.7 ± 1.2 (oxycodone/naloxone; difference in means −0.14 \[95% CI, −0.42 to 0.13\]; *p* = 0.3. Mean maximum pain at rest in the first 24 h after surgery was 2.6 ± 2.0 (tapentadol) and 2.8 ± 2.0 (oxycodone/naloxone; difference in means −0.23 \[95% CI, −0.71 to 0.25\]; *p* = 0.3) and decreased to 0.8 ± 1.0 (tapentadol) and 1.0 ± 1.4 (oxycodone/naloxone; difference in means −0.25 \[95% CI, −0.04 to 0.54\]; *p* = 0.1) on day 5. Maximum pain levels at rest over five post-operative days beginning with the day of the operation (day 1) are depicted in Fig. [3](#Fig3){ref-type="fig"} A. Median pain at rest on day 1 was surprisingly low (\<2) in the tapentadol group despite the fact that in the tapentadol group patients had received lower doses of long-acting opioids intra-operatively.

Mean equianalgesic daily dose of study medication over the 5-days observation period did not differ between the groups. The mean daily oxycodone equivalent dose was 19.0 ± 9.4 mg (tapentadol) versus 18.5 ± 9.4 mg (oxycodone/naloxone; difference in means 0.52 \[95% CI, −1.73 to 2.77\]; *p* = 0.6). Daily doses of post-operative study medication during the 5-days observation period are depicted in Fig. [4](#Fig4){ref-type="fig"}.Fig. 4Post-operative daily dose of study medication (mg): Previous studies have shown that 50 mg of tapentadol is the equivalent dose to 10 mg of oxycodone. The following *boxplot* has two y-axes for the doses of each treatment arm. *Box edges* indicate 25th and 75th percentiles. Whiskers indicate 5th and 95th percentiles. Mean daily dose of study medication over the 5-days observation period did not differ between the groups

The cumulative doses of study medication for the different types of procedures are depicted in Table [3](#Tab3){ref-type="table"}. Reconstructions of ligaments and muscle like rotator cuff repair or anterior cruciate ligament reconstruction were associated with the highest doses of study medication.Table 3Cumulative study medication during the 5-days observation period for the different types of proceduresOperationCumulative study medication (mg)Tapentadol\
(mean ± std)Oxycodone/naloxone\
(mean ± std)Open reduction and internal fixation, ORIF449 ± 22894 ± 48Closed reposition and intramedullary nailing540 ± 23882 ± 34Joint replacement567 ± 30381 ± 43Reconstruction of ligaments and muscle580 ± 199104 ± 64Fixateur externe700.

Secondary results: effects of sex and BMI, differences between the study sites {#Sec17}
------------------------------------------------------------------------------

The effect of female sex on pain during exercise was not significant (difference in means 0.27 \[95% CI, −0.058 to 0.59\]; *p* = 0.1). Analyses additionally adjusted for BMI gave the same results like the primary analysis. Female sex was an independent risk factor for the occurrence of side effects (Odds Ratio 3.3 \[95% CI 1.9 to 5.8\]; *p* \< 0.001). BMI had no significant influence on the incidence of side effects (i.e. no effect greater than 6% with 95% confidence;Odds Ratio 1.0 \[95% CI 0.95 to 1.06\]; *p* = 0.8).

Subgroup analysis of the primary hypotheses at the two study sites yielded the same results as the primary analysis. However, there were differences between the study sites which, apparently, did not affect the primary results: Mean (±SD) duration of the operation was 88 ± 44 min. at study site 1 and 68 ± 38 min. at study site 2 (*p* \< 0.01) and only 60% of patients received intra-operative sufentanil or fentanyl at study site 1 (compared to 90% at study site 2). Mean daily pain intensities were significantly higher at study site 1 compared to study site 2: Mean pain during exercise was 3.1 ± 1.4 (study site 1, mean ± SD) vs. 2.5 ± 1.2 (study site 2; difference in means 0.61 \[95% CI 0.30 to 0.92\]; *p* \< 0.001). Patients at study site 1 received higher mean daily doses of study medication for the first three days. Mean daily oxycodone equivalent dose over 5 days was 20.3 ± 9.1 mg (study site 1) vs. 17.3 ± 9.5 mg (study site 2; difference in means 3.0 \[95% CI, 0.75 to 5.26\]; *p* \< 0.01). As a consequence, the incidence of relevant AEs was 62% at study site 1 compared to 38% at study site 2 (*p* \< 0.001). Study site 1 was associated with a higher risk for side effects in the multivariate logistic regression model, probably as a result of higher doses of study medication (Odds Ratio 2.9 \[95% CI 1.7 to 4.9\]; *p* \< 0.001).

Separate analysis of patients with unacceptably higher pain scores at the end of the observation period (pain at rest ≥5 on days 4 or 5) {#Sec18}
----------------------------------------------------------------------------------------------------------------------------------------

Higher pain scores at the end of the observation period in seven patients were in one case explained by inconsistencies with the non-blinded observation; in three cases study medication had been discontinued on day 2, in one case there was a surgical problem with an incorrectly placed splint. One patient (oxycodone/naloxone) had developed anxiety disorder with high pain scores unresponsive to opioid medication, in one patient (tapentadol) high pain scores were resulting from pre-existing spinal stenosis, not from pain at the operation site which was well controlled with low doses of study medication.

Secondary results: treatment duration and patient satisfaction {#Sec19}
--------------------------------------------------------------

There were no differences regarding mean treatment duration with study medication (4.1 days in each treatment arm; mean difference 0.02 \[95% CI, −0.49 to 0.46\]; *p* = 0.95). Most patients were satisfied with their treatment. On a scale of 0 (very satisfied) to 10 (not satisfied at all) the mean score was 2.3 in the tapentadol group and 2.1 in the oxycodone/naloxone group (mean difference 0.14 \[95% CI, −0.16 to 0.43\]; *p* = 0.4). Patient satisfaction scores are depicted in Fig. [5](#Fig5){ref-type="fig"}.Fig. 5Patient satisfaction at the end of the study period from 0 (=very satisfied) to 10 (= not satisfied at all)

Secondary results: unexpected adverse events {#Sec20}
--------------------------------------------

The allover incidence of unexpected adverse events was comparable in the treatment arms (see Table [4](#Tab4){ref-type="table"}). Only one SAE occurred unrelated to the study (oxycodone/naloxone group): A 90-year-old patient experienced a fatal pulmonary embolism confirmed by echocardiography following insertion of a femoral head prosthesis. Unexpected central nervous side effects probably related to the study medication were one case of optical hallucinations in the tapentadol group, one case of severe anxiety disorder and 4 cases of agitation and sleeplessness after discontinuation of study medication which we interpreted as withdrawl reactions in the oxycodone/naloxone group.Table 4Incidence of unexpected adverse eventsSide effectTapentadol\
*N* = 133Oxycodone/Naloxone\
N-133CommentaryCentral-nervous side effects Confusion3 (0)Confusion was observed in the immediate post-operative period, neurologic function recovered spontaneously while study medication was continued Delirium1 (1)Delirium developed on treatment day 2 (20/10 mg daily dose), and resolved on day4 after discontinuation of study medication Convulsion1 (0)Patient had a history of convulsions upon stress and sleep deprivation Optical hallucinations (yellow circles)1 (1)Hallucinations disappeared two days after discontinuation of study medicationMood disorders Euphoria, increased talkativeness2 (2)Euphoria resolved after dose reduction Anxiety1 (1)Anxiety and catastrophizing reaction resolved when study medication was discontinued Sleeplessness and agitation4 (4)Sleeplessness and agitation occurred following withdrawl of study medicationCardio-vascular side effects Hypertension1 (0)1 (0)Hypertension was noted pre-operatively Dysrhythmia1 (0)Dysrhythmia was diagnosed pre-operatively Hypotension1 (1)Blood pressure was restored to normal when study medication was discontinuedOther minor side effects Skin rash1 (0)1 (0) Sweating3 (1)5 (3)4 cases attributed to metamizol Dry mouth3 (3)2 (2)(5) ameliorated after dose reduction Aching stomach, heartburn5 (1)3 (1)(2) ameliorated after dose reduction Diarrhea1 (0)1 (0) Headache1 (0)N = number of patients affected, in brackets number of cases potentially related to study medication

Discussion {#Sec21}
==========

Comparison of both analgesia concepts -analgesic efficacy and incidence of side effects {#Sec22}
---------------------------------------------------------------------------------------

This study shows that a time-scheduled oral regimen with either extended-release tapentadol or oxycodone/naloxone in combination with non-opioid analgesics provided reliable pain relief following trauma/orthopedic surgery procedures- where pain management is still especially challenging. It is worth noting that mean NRS values for worst pain during exercise on the day of the operation (day 1) were \<4 in our study in both groups- compared to 6--7 for trauma/orthopedic surgery in the large prospective cohort study presented by Gerbershagen et al. \[[@CR1]\].

Our main hypothesis -non-inferiority of tapentadol compared to oxycodone/naloxone regarding pain during exercise- was confirmed, but neither non-inferiority of tapentadol with respect to side effect incidence nor superiority for analgesic efficacy and/ or side effect incidence could be established.

Still, the remarkably low median level of pain at rest on day 1 in the tapentadol group seen in our study merits further attention as it has been suggested that adrenergic descending inhibitory systems might be of potential relevance in (1) attenuating remifentanil-induced post-infusion hyperalgesia and anti-analgesia \[[@CR18]\], and (2) in determining the time course of recovery from hypersensitivity after surgery \[[@CR19]\].

The lower incidence of nausea and vomiting seen in tapentadol-treated patients could in part be explained by confounding factors of PONV (patients in the tapentadol group received more frequently a prophylaxis). Due to the differing use of PONV prophylaxis we could not show superiority of tapentadol with respect to PONV in this study. It has previously been established that the prevalence of nausea and vomiting in patients requiring opioids for post-operative analgesia (i.e. that have at least one risk factor) ranges between 21 and 79% \[[@CR20]\]. The comparably high tolerability of both tapentadol and oxycodone/naloxone with respect to nausea and vomiting seen in our study may also be due to the extended-release formulation: The intermediate-release formulation of tapentadol was associated with an even higher incidence of nausea and vomiting (19% vomiting) when compared to oxycodone for acute post-operative pain relief after elective arthroscopic shoulder surgery \[[@CR21]\]. In trials using intravenous patient-controlled analgesia 20--30% of patients presented with nausea and vomiting during the whole period of opiate requirement preventing patients from continuing opioid therapy \[[@CR22]\]. The observation that the extended-release formulations apparently increase tolerability reaffirm the well-established concept that opioids are more dose-effective when stable plasma concentrations can be achieved over the whole duration of the painful stimulus \[[@CR23]\].

Both oxycodone/naloxone and tapentadol were associated with a lower risk of constipation in trauma surgery patients compared to oxycodone without naloxone where the risk of constipation was 46% in trauma surgery patients \[[@CR7]\].

However, despite higher gastro-intestinal tolerability of oxycodone/naloxone and tapentadol compared to i.v. opioids or oxycodone without naloxone, the problem of opioid-induced gastro-intestinal side effects in trauma surgery patients is not yet solved. Thus, based on our results, we recommend that established principles for the prophylaxis against PONV and opioid-induced constipation are pre-emptively applied in trauma surgery patients receiving opioids. Severe central nervous side effects like somnolence and/or confusion were rare (\< 2%) and probably unrelated to study medications as neurologic function recovered spontaneously while study medication was continued. Only in one patient receiving 20/10 mg daily dose of oxycodone/naloxone study medication had to be discontinued due to delirium. No patient had opioid induced respiratory depression that required reversal with iv naloxone. Anxiety, sleeplessness and agitation was only seen in patients allocated to oxycodone/naloxone- in one patient anxiety resolved when oxycodone/naloxone was discontinued, in four cases agitation and sleeplessness occurred when oxycodone/naloxone had been withdrawn. These results indicate that psychomimetic effects of oxycodone and oxycodone withdrawal might constitute a problem even during short-term use.

The primary results on the effects of study medication were reproduced at two different study sites- despite the differences between the study sites with respect to duration of the operations and intra-operative opioid analgesic management. The fact that there was no association between sex, BMI and post-operative pain during exercise in trauma/orthopedic surgery is in accordance with a recent study showing no sex difference in post-operative pain in the joint surgery group \[[@CR24]\].

Non-responders {#Sec23}
--------------

In six /264 patients no acceptable pain relief (NRS \< 5) was provided by either treatment until day 4 or 5 of treatment duration. In three patients management has been inadequate (study medication discontinued at an early stage). In the three remaining patients, not responding to either tapentadol or oxycodone/naloxone was indicative of either a surgical problem or a wider, more complex medical issue (anxiety disorder/ neuropathic pain due to spinal stenosis) requiring particular attention by an experienced pain specialist. Thus, as previously suggested \[[@CR25]\], it seems important to achieve effective analgesia in the early postoperative period and continue post-operative opioid treatment only as long as the nociceptive input from the wound persists after surgery. Patients that do not get pain-free during that time should be evaluated by a specialist in pain medicine and receive specific, preferably non-opioid treatment.

Limitations of the study {#Sec24}
------------------------

The aim of our study was to evaluate and compare the efficacy and safety of both opioid-based analgesic regimens under the conditions of daily practice in our trauma surgery departments. As a consequence, there was a considerable heterogeneity in the types of surgeries performed, even within one category (i.e. open reduction and internal fixation- radial vs. femoral fracture) which might constitute a confounding factor. The postoperative exercise protocols differed with regard to the degree of mobilization and pain intensity. Still, it is interesting to note that while joint procedures are usually predicted to have the greater post-procedural pain, the amount of morphine equivalents consumed within that surgical category was similar to all other categories. Reconstructions of ligaments and muscle like rotator cuff repair or anterior cruciate ligament reconstruction were associated with the highest doses of study medication. However, the relatively small subgroup sizes limit the generalizability of these results. Another shortcoming of our study was the lack of patient blinding which might have biased the results.

Conclusions {#Sec25}
===========

Both the tapentadol- as well as the oxycodone/naloxone-based perioperative multimodal oral analgesia concept provided reliable post-operative pain relief with mean pain scores over five days below 2 at rest and below 3 during exercise. The most common side effects were gastro-intestinal implying that trauma surgery patients receiving opioids might benefit from a routine prophylaxis against PONV and constipation. Analgesic failure with high pain levels at the end of the observation period despite continuing opioid medication was low (\<2%) -- and indicative of either a surgical problem or a complex pain condition independent from surgery. Severe anxiety and signs of withdrawl even after short-term use was only seen in oxycodone/naloxone- treated patients.

This study supports the existing clinical evidence in favor of the peri-operative use of oral extended-release opioids. Severe opioid-induced side effects like respiratory depression resulting in hypoxemic brain damage or death have been shown to be almost entirely associated with parenteral routes of opioid administration or combinations of different opioids \[[@CR26]\]. For safety reasons, extended-release oral opioids should only be used in patients that have no restrictions for oral intake.

Appendix 1 {#Sec26}
==========

Table 5Concomitant perioperative opioid analgesia in mg METapentadol *N*=133Oxycodone/Naloxone *N*=133Total *N*=266Dose of intra-OP fentanyl (mg ME) N6359122 MEAN13.415.714.5 STD6.710.08.5  *p*-VALUE (T-TEST)0.15Dose of intra-OP sufentanil (mg ME) N364278 MEAN15.821.919.1 STD8.615.513.1  *p*-VALUE (T-TEST)0.03Dose of intra-OP piritramide (mg ME) N6752119 MEAN6.06.36.1 STD2.72.62.7  *p*-VALUE (T-TEST)0.6Dose of intra-OP fentanyl or sufentanil and/or piritramide (mg ME) N126124250 None7714 MEAN14.417.515.9 STD8.813.011.2  *p*-VALUE (T-TEST)0.03Dose of piritramide post-OP (mg ME) N10297199 None313667 MEAN8.07.08.0 STD4.13.23.7  *p*-VALUE (T-TEST)0.18

Appendix 2 {#Sec27}
==========

Table 6Non-opioid analgesic medicationTapentadolOxycodone/NaloxoneNMeanNMean*p*-value (Chi^2^)*p*-value (t-test)Acetaminophen (mg) Day 17221441875 Day 28331363333 Day 311272763166 Day 410275063667 Day 57328673429 Total over 5 days1676569102780.140.32Dipyrone (mg) Day 112734841243598 Day 211833531143338 Day 310733391053300 Day 4993247953276 Day 5753127803163 Total over 5 days13013473127136050.310.85Ibuprofen (mg) Day 14487338953 Day 2681515661424 Day 3681526641469 Day 4701526601440 Day 5671460591403 Total over 5 days7659186758720.270.89Etoricoxib (mg) Day 13100584 Day 2390584 Day 3290584 Day 4390483 Day 5390483 Total over 5 days621563201.000.24Celecoxib (mg) Day 1001200 Day 20000 Day 3001200 Day 4001200 Day 5001200 Total over 5 days0024000.16-Parecoxib (mg) Day 113401340 Day 20000 Day 30000 Day 40000 Day 50000 Total over 5 days134013401.001.00Number of patients with the respective cumulative non-opioid pain medication in mg at day x and/ or more than 1 day "Total over 5 days"

Appendix 3 {#Sec28}
==========

Table 7Rescue medication against nausea and vomitingTapentadolOxycodone/NaloxoneNMean doseNMean dose*p*-value\
(Chi^2^)*p*-value\
(t-test)Metoclopramide (mg) Day 1911911 Day 261188 Day 3411510 Day 4313210 Day 5312120 Total over 5 days151921120.280.24Ondansetron (mg) Day 187166 Day 23765 Day 346210 Day 411218 Day 52400 Total over 5 days12101980.180.52Dimenhydrinate (mg) Day 1162162 Day 20000 Day 30000 Day 40000 Day 50000 Total over 5 days1621621.00-Droperidol (mg) Day 111.2513.75 Total over 5 days11.2513.750.99-Number of patients with the respective rescue medication in mg at day x and/ or more than 1 day "Total over 5 days"

Appendix 4 {#Sec29}
==========

Table 8Rescue medication against constipationTapentadolOxycodone/\
NaloxoneNMean doseNMean dose*p*-value\
(Chi^2^)*p*-value\
(t-test)PEG3350 (g) Day 10017 Day 2628324 Day 312271022 Day 41228825 Day 51032924 Total over 5 days176813550.440.47Sodium picosulfate (mg) Day 10000 Day 211000 Day 331036 Day 469210 Day 52800 Total over 5 days1011570.180.07Bisacodyl (mg) Day 11500 Day 20000 Day 30000 Day 421015 Day 512000 Total over 5 days411150.180.44Lactulose (g) Day 10000 Day 20017 Day 30017 Day 421017 Day 521317 Total over 5 days316470.700.13Number of patients with the respective rescue medication in mg at day x and/ or more than 1 day "Total over 5 days"

AE

:   Adverse event

ASA

:   Health status according to the American society of anesthesiology

CI

:   Confidence interval

CL

:   Confidence limit

ER

:   Extended release

IR

:   Intermediate release

ITT

:   Intention to treat

MAX

:   Maximum

ME

:   Morphine equivalent

MIN

:   Minimum

NRS

:   Numeric rating scale (from 0 = no pain to 10 = max. Pain)

PCA

:   Patient-controlled analgesia

PONV

:   Post-operative nausea and vomiting

PP

:   Per-protocol

SAE

:   Serious adverse event

SD

:   Standard deviation
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